Exchange: NASDAQ·Updated 07:55 PM EST

ETON News

News
all
press releases
Earnings Estimates Moving Higher for Eton Pharmaceuticals (ETON): Time to Buy?
Eton Pharmaceuticals, Inc. (ETON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
Earnings Estimates Moving Higher for Eton Pharmaceuticals (ETON): Time to Buy?
Eton Pharmaceuticals, Inc. (ETON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
More News
Regeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.
Zacks
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
Zacks
Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have given a...
MarketBeat
Eton Pharmaceuticals: The Commercial Model Is Finally Scaling...
SeekingAlpha
Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON) sharesread more...
Benzinga
ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
Zacks
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of +211.77% and +37.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
Zacks
Eton Pharmaceuticals licenses Aquestive's LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.read more...
Benzinga

Advertisement|Remove ads.